May 14th 2007 --- Endothelix, Inc announces its move into a new facility. The 3,000 plus square foot space houses research & development, administrative and corporate offices. The building incorporates state of the art A/V conferencing and advanced computer networking technologies.
The office is conveniently located in the south side of the Texas Medical Center in the growing area of Genesis Biotechnology Park. The Park, an initiative supported by Western General and BioHouston organization, is home to a number of local emerging biotechnology companies.
“The move is an important step in the progression of Endothelix from a start-up company to a leader in the field of cardiovascular function monitoring and risk assessment” said President and CEO, Morteza Naghavi, M.D. The new facility places Endothelix in the heart of Houston’s Biotechnology community where Endothelix foresees future expansion.
“We are delighted to see Endothelix growing fast. It is BioHouston’s mission to help companies like Endothelix advance.” said Jacqueline Northcut, President and CEO of BioHouston.
Endothelix is striving to fill in the gap between measurement of risk factors of cardiovascular disease such as blood pressure, cholesterol, diabetes etc., and advanced cardiac imaging technologies such as MRI and CAT scan. With its extensive proprietary technologies the company has positioned itself to lead the emerging field of non-invasive, non-imaging cardiovascular health monitoring. The company aims to replace existing blood pressure measurement devices with its VENDYS® platform which not only measures blood pressure but also evaluates micro and macro vascular function. Endothelix’s technologies can empower practicing family physicians to practice like preventive cardiologists.
In addition to heart attack and stroke, impaired endothelial function is associated with diabetes, heart failure, kidney disease, and Alzheimer’s. Endothelix has positioned itself as the first endothelial function monitoring company with comprehensive Micro and Macro vascular endothelial function monitoring technologies. The company is growing its IP portfolio to maintain its leadership.
About: Endothelix, a Houston Technology Center Client company,
is a Delaware
corporation based in Houston, Texas
and was formed in December 2003. The company is dedicated to enabling physicians to monitor their patients'' vascular function and to apply appropriate therapies. The company is pursuing an array of innovative technologies to fulfill its mission. The immediate focus of the company is to implement non-invasive non-imaging vascular function monitoring in cardiovascular risk assessment for prevention of heart attack and stroke. More information is available at www.endothelix.com
About Houston Technology Center: Houston Technology Center, a business accelerator and the largest technology business incubator in Texas, accelerates the commercialization of emerging technology companies in the Greater Houston area. A 501(C)(3) corporation, HTC assists Houston-based entrepreneurs within several key sectors: Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies, by providing in-depth business guidance, access to capital and service providers, and entrepreneurial education. For more information, visit www.houstontech.org.